Isabel Carulli
A5031010115- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- Ovarian cancer diagnosis and treatment
- Reproductive System and Pregnancy
- Immune cells in cancer
- vaccines and immunoinformatics approaches
- COVID-19 Clinical Research Studies
- Plant Virus Research Studies
- SARS-CoV-2 and COVID-19 Research
- Immunotherapy and Immune Responses
- Polyomavirus and related diseases
- Bacteriophages and microbial interactions
- Renal cell carcinoma treatment
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Respiratory viral infections research
- Cytomegalovirus and herpesvirus research
- RNA modifications and cancer
- Cancer Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Phagocytosis and Immune Regulation
Dana-Farber Cancer Institute
2021-2025
T cell-mediated immunity plays an important role in controlling SARS-CoV-2 infection, but the repertoire of naturally processed and presented viral epitopes on class I human leukocyte antigen (HLA-I) remains uncharacterized. Here, we report first HLA-I immunopeptidome two cell lines at different times post infection using mass spectrometry. We found peptides derived not only from canonical open reading frames (ORFs) also internal out-of-frame ORFs spike nucleocapsid captured by current...
Personalized cancer vaccines (PCVs) can generate circulating immune responses against predicted neoantigens1–6. However, whether such target driver mutations, lead to recognition of a patient's tumour and result in clinical activity are largely unknown. These questions particular interest for patients who have tumours with low mutational burden. Here we conducted phase I trial (ClinicalTrials.gov identifier NCT02950766) test neoantigen-targeting PCV high-risk, fully resected clear cell renal...
Background Cytokine release triggered by a hyperactive immune response is thought to contribute severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2)–related failure. Bruton tyrosine kinase (BTK) involved in innate immunity, and BTK inhibitors block cytokine release. We assessed the next-generation inhibitor zanubrutinib SARS-CoV-2–infected patients with distress. Method Cohort 1 had prospective, randomized, double-blind, placebo-controlled design; cohort 2 single-arm design....
Clear cell renal carcinoma (ccRCC), despite having a low mutational burden, is considered immunogenic because it occasionally undergoes spontaneous regressions and often responds to immunotherapies. The signature lesion in ccRCC inactivation of the VHL tumor suppressor gene consequent upregulation HIF transcription factor. An earlier case report described patient who was cured by an allogeneic stem transplant later found have donor-derived T cells that recognized ccRCC-specific peptide...
Cancers avoid immune surveillance through an array of mechanisms, including perturbation HLA class I antigen presentation. Merkel cell carcinoma (MCC) is aggressive, HLA-I-low, neuroendocrine the skin often caused by polyomavirus (MCPyV). Through characterization 11 newly generated MCC patient-derived lines, we identified transcriptional suppression several presentation genes. To systematically identify regulators HLA-I loss in MCC, performed parallel, genome-scale, gain- and...
Although local tissue-based immune responses are critical for elucidating direct tumor-immune cell interactions, peripheral increasingly recognized as occupying an important role in anticancer immunity. We evaluated serial blood samples from patients with advanced epithelial ovarian cancer (EOC) undergoing standard-of-care neoadjuvant carboplatin and paclitaxel chemotherapy (including dexamethasone prophylaxis of paclitaxel-associated hypersensitivity reactions) to characterize the evolution...
Severe respiratory illness is the most prominent manifestation of patients infected with SARS-CoV-2, and yet molecular mechanisms underlying severe lung disease in COVID-19 affected still require elucidation. Human leukocyte antigen class I (HLA-I) expression crucial for presentation host's response to SARS-CoV-2.
Abstract Personalized cancer vaccines can generate circulating immune responses against predicted neoantigen targets, but whether such lead to actual recognition of a patient’s tumor and consequent clinical activity is largely unknown. To investigate this, we conducted phase I trial personalized vaccine as adjuvant therapy in high-risk, completely surgically resected, stage III/IV clear cell renal carcinoma (RCC; NCT02950766). This first-in-disease study included several modifications from...
Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Supplementary Data from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer